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BACKGROUND: Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35
ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed
post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant
treatment.
METHODS: Prognostic and predictive values of post-operative CEA in patients with stage II CC were evaluated with Kaplan–Meier
survival curves and Cox model with interaction terms. Disease-free survival (DFS) and overall survival (OS) were estimated.
RESULTS: Among 899 stage II CC patients, post-operative CEA was available in 867 (96.4%); and 434 (48.65%) had a high-risk stage
II disease. The 3-year DFS rate was 88.5% and 78.7% in the ≤ 2.35 ng/mL and > 2.35 ng/mL group, respectively (P= 0.006). Use of
oxaliplatin showed survival benefit only in patients with high-risk stage II CC and post-operative CEA > 2.35 ng/ml (interaction term
P= 0.09 and 0.03 for DFS and OS).
CONCLUSION: CEA is a strong prognostic factor for DFS and OS in stage II CC. In the MOSAIC trial, only high-risk stage II CC patients
with post-operative CEA > 2.35 ng/mL benefited from the addition of oxaliplatin to LV5FU2.
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BACKGROUND
Colon cancer (CC) is the third most common cancer in men and
women.1,2 Seventy-five percent of the patients are diagnosed at
a localised stage; where a curative treatment can be proposed.
Although adjuvant chemotherapy after curative surgery is
recommended for stage III CC patients,3 its survival benefit for
stage II CC is still debated. In this latter group of patients,
adjuvant fluoropyrimidine-based chemotherapy with or without
oxaliplatin is used. The results of subgroups analyses of large
adjuvant trials and meta-analysis have demonstrated several
risk factors for recurrence or death in stage II CC that guide
adjuvant treatment decisions.3 In the MOSAIC trial, the
estimated 10-year probability of overall survival (OS) was
75.4% for FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)
and 71.7% for LV5FU2 (fluorouracil and leucovorin)4,5 in high-
risk CC patients with a simplified definition of high-risk stage II
disease (T4, tumour perforation, or <10 examined lymph nodes).
In this study, the addition of oxaliplatin to LV5FU2 did not
provide any survival benefit for low-risk stage II CC patients.
Nowadays, there is a need to better identify patients for whom
the addition of oxaliplatin to LV5FU2 can reduce disease relapse
or death, but also to limit useless long-lasting toxicities induced
by oxaliplatin.
Carcinoembryonic antigen (CEA) is a well-known low cost
biological tumour marker used in CC since 1965.6 Previous large
studies have shown that elevated pre-operative CEA levels are
associated with worse prognosis in patients with stage I and II
disease, who did not receive adjuvant chemotherapy, and for
whom pre-operative CEA value of 2.35 ng/mL was defined as an
optimal cut-off point for survival stratification.7
The aims of this post hoc study were (i) to assess and validate
precisely the prognostic value of post-operative CEA for disease-
free survival (DFS) and OS in patients with stage II CC treated by
adjuvant chemotherapy and (ii) to determine the additional
predictive value of post-operative CEA for the benefit of the
addition of oxaliplatin to LV5FU2.
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METHODS
Population
All stage II CC patients from the MOSAIC phase III trial
(NCT00275210) were included in this post hoc analysis.4 Post-
operative CEA <10 ng/mL was an inclusion criterion in the MOSAIC
trial. The CEA measurement was not centralised.
Definition of high-risk stage II CC
High-risk stage II CC was defined as being characterised by one of
the following factors: T4, tumour perforation, and <10 or <12
examined lymph nodes (the MOSAIC definition and the modified
MOSAIC definition, respectively).
Statistical analysis
Median values (interquartile range) and frequencies (percentage)
were provided for the description of continuous and categorical
variables, respectively. Medians and proportions were compared
using Student’s t-test and chi-square test (or Fisher’s exact test, if
appropriate), respectively.
DFS was defined as the time between randomisation and local/
distant relapse, second colorectal/rectal occurrence, or death,
whichever occurred first. Alive patients without relapse and
second colorectal/rectal cancer were censored at the date of
their last follow-up.
OS was defined as the time between randomisation and death
from any cause. Patients known to be alive were censored at the
date of their last follow-up.
DFS and OS were estimated using the Kaplan–Meier method
and described using median or rate at specific time points with
their 95% confidence intervals (95% CIs). Follow-up was calculated
using the reverse Kaplan–Meier method.
When used continuously, the association between CEA and
survival was investigated with the restricted cubic splines method
with graphical evaluation. When used as a categorical variable, the
CEA cut-point defined by Margalit et al. in a cohort of 45 449 stage
I-II CC patients was applied. A sensitivity analysis was performed
with the Horton and Lausen method to find the best CEA cut-off
for risk stratification in our cohort.8
The association of demographic, clinical, biological and
molecular factors with survival was first assessed by the univariate
Cox-proportional-hazard model, providing hazard ratios (HRs) and
95% CIs. Parameters with P-values of <0.10 in univariate analysis
and/or clinically relevant variables were entered into the multi-
variable Cox-regression model.
A differential DFS and OS treatment effect among the identified
CEA risk groups but also when considering the CEA risk groups
identified as an additional parameter to include in classical well-
established risk group definitions was evaluated with an interaction
term in the Cox-regression model and illustrated with Kaplan–Meier
curves.
All analyses were performed using SAS version 9.4 (SAS
Institute, Cary NC) and R software version 2.15.2 (R Development
Core Team, Vienna, Austria; http://www.r-project.org). P-values of
<0.05 were considered statistically significant and a threshold of
0.1 was used for interaction terms. All tests were two-sided.
RESULTS
Characteristics of patients
Among the 2246 patients included in the MOSAIC trial, 899
had stage II CC. Post-operative CEA was available in 867
(96.4%) patients; 834 (96.2%) had CEA <5 ng/mL and 664
(76.6%) <2.35 ng/mL.
Overall, 434 (48.65%) and 520 (58.3%) patients had high-risk
stage II CC according to the MOSAIC and the modified MOSAIC
definition, respectively (Table 1). The MSI status was well balanced
between patients with CEA <2.35 and >2.35 ng/mL (12.4% vs
16.3%, P= 0.36).
Post-operative CEA and survival
When post-operative CEA was used as continuous variable, a
gradual risk suggesting a linear relation between post-operative
CEA and DFS and OS was identified (Fig. 1). Different risk
populations among patients with a post-operative CEA level of
<5 ng/mL were determined. This result validates in our cohort the
lower cut-off of 2.35 ng/mL found by Margalit et al.




Age at inclusion, years ≤ 70 798 (88.77%)
> 70 101 (11.23%)
Gendera Female 407 (45.27%)
Male 492 (54.73%)




Type of adjuvant chemotherapya FOLFOX4 451 (50.17%)
LV5FU2 448 (49.83%)
Tumour locationa Left 580 (64.52%)
Right 319 (35.48%)
Histoprognostic grade G1/2 763 (89.55%)
G3/4 89 (10.45%)
Missing 47
Stage II risk group Highb 434 (48.65%)
(MOSAIC definition) Lowc 458 (51.35%)
Missing 7
Stage II risk group High 520 (58.3%)
(modified MOSAIC definition) Low 372 (41.7%)
Missing 7
T-stagea T3 728 (80.98%)
T4 171 (19.02%)
Number of nodes examineda Median (IQR) 12 (8–19)
Performance status* 0–1 799 (88.9%)
≥ 2 100 (11.1%)
Bowel perforationa 81 (9.01%)
Bowel obstructiona 158 (17.58%)
Vascular invasion Yes 80 (16.29%)
Missing 408
MMR status dMMR 48 (13.15%)
pMMR 317 (86.85%)
Missing 534
CEA level, ng/mL Median (IQR) 1.4 (0.9–2.2)
standard CEA cut-off level, ng/mL ≤ 5 834 (96.19%)
> 5 33 (3.81%)














Time between surgery and CEA
measurement, weeks
Median (IQR) 4.4 (3.3–5.4)
Follow-up, years Median Median 8.8 (7.9–9.5)
CC colon cancer, MMR mismatch repair, CEA carcinoembryonic antigen, CI
confidence interval, IQR interquartile range
ano missing data
bT4, tumour perforation, or fewer than 10 lymph nodes examined
cT1–3 and no tumour perforation and 10 or more lymph nodes examine
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When post-operative CEA was used as a categorical variable, a
strong trend was observed between ≤5 and >5 ng/mL values and
DFS, with the 3-year DFS rate of 86.6% and 75.5% in the ≤ 5 and >
5 ng/mL groups, respectively; P= 0.53. However, the difference
was not significant (Fig. 2a).
When using the 2.35 ng/mL cut-off identified by Margalit et al,
patients with a post-operative CEA level ≤2.35 ng/mL were at
lower risk of recurrence or death. The 3-year DFS rate was 88.5 and
78.7% for patients with CEA ≤2.35 ng/mL and >2.35 ng/mL,
respectively (P= 0.006; Fig. 2b).
Similar results were observed with OS (Supplementary Fig. S1). In
the sensitivity analysis, a threshold value of 2.77 ng/mL was identified
as the optimal CEA cut-off (Supplementary Figs. S2 and S3).
Independent prognostic value of post-operative CEA
In univariate analysis, a post-operative CEA level of >2.35 ng/mL
was associated with DFS and OS (DFS: HR 1.51, 95% CI 1.12–2.03;
P= 0.006 and OS: HR 1.46, 95% CI 1.05–2.05; P= 0.03).
After adjustment for age, gender, tumour location, bowel
obstruction, and MOSAIC risk group, CEA >2.35 ng/mL was
still significantly associated with DFS (HR 1.49, 95% CI 1.10–2.00;
P= 0.009) and OS (HR 1.90, 95% CI 1.33–2.72; P < 0.0001; Table 2
and Supplementary Table S1).
Predictive value of post-operative CEA
The benefit of the addition of oxaliplatin to LV5FU2 in term
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Fig. 2 DFS according to (a) CEA 5 ng/mL and CEA 2.35 ng/mL (b)
Table 2. Multivariate Cox-regression analysis of DFS (N= 860)
HR 95% CI P
Age, years >70 1.94 1.37–2.76 <0.0001
Gender Male 1.35 1.02–1.79 0.035
Tumour location Right 0.78 0.58–1.06 0.111
MOSAIC risk group Low 0.74 0.56–0.98 0.035
Bowel obstruction Yes 1.48 1.07–2.03 0.016
CEA level, ng/mL > 2.35 1.49 1.10–2.00 0.009
HR hazard ratio, CI confidence interval, CEA carcinoembryonic antigen
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(Table 3 and Supplementary Table S2). Only patients with high
post-operative CEA levels seemed to have survival benefit from
oxaliplatin addition to LV5FU2 (interaction terms P= 0.09;
Fig. 3a).
Among patients with high post-operative CEA levels, the benefit
from oxaliplatin addition was observed in the high-risk stage II CC
patients (DFS interaction term P= 0.09 and OS interaction term
P= 0.03), but not in those with low-risk stage tumours (DFS
Table 3. Disease-free survival according to treatment arm and CEA level
DFS
3 y % (95% CI) P-value for the interaction term
between CEA (≤ 2.35, > 2.35) and











Whole population 899 448 451 84.7 (81.4–88.1) 87.1 (84–90) +2.4 +2.8 0.11
CEA ≤2.35 664 333 331 88.2 (84.8–91.7) 88.7 (85.4–92.2) +0.5 +0.6 1.07 (0.77–1.47)
CEA >2.35 203 97 106 76 (67.9–85.1) 81.1 (74–88.9) +5.1 +6.7 0.67 (0.41–1.11)
High-riska population 434 222 212 81.3 (76.2–86.6) 86.3 (81.7–91) +5 +6.1 0.09
High-risk - CEA ≤2.35 320 158 162 84 (78.4–89.9) 86.3 (81.2–91.8) +2.3 +2.7 0.95 (0.62–1.45)
High-risk - CEA >2.35 102 55 47 74 (63.2–86.7) 87.2 (78.2–97.3 +13.2 +17.8 0.47 (0.23–0.97)
Low-riskb population 458 223 235 87.9 (83.7–92.3) 88 (83.9–92.3) +0.1 +0.1 0.78
Low-risk - CEA ≤2.35 338 172 166 91.8 (87.8–96) 91.5 (87.3–95.8) −0.3 −0.3 1.18 (0.71–1.95)
Low-risk - CEA >2.35 100 42 58 78.6 (67.1–92) 75.8 (65.6–87.7) −2.8 −3.6 0.99 (0.47–2.10)
Absolute difference at time X gives the difference between percentages observed in the two treatment arms at time X; the relative difference at time X gives the
proportion of increase or decrease in survival rate of one arm relative to the other arm at time X
aT4, tumour perforation, or fewer than 10 lymph nodes examined
bT1–3 and no tumour perforation and 10 or more lymph nodes examined
cHR for treatment effect (the addition of oxaliplatin to the LV5FU2 regimen)
dAbsolute difference reflects a comparison of survival between the FOLFOX and LV5FU2 arms
eRelative difference reflects a ratio of the observed survival in the FOLFOX arm and the LV5FU2 arm [(X year OS rate in the FOLFOX group - X year OS rate in






















































No. at risk No. at risk No. at risk
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Fig. 3 Benefit for DFS with the addition of oxaliplatin to LV5FU2 in a all patients, b the MOSAIC low-risk patients, c the MOSAIC low-risk
patients after CEA stratification, d the MOSAIC high-risk patients, and e the MOSAIC high-risk patients after CEA stratification. Figure 3
abbreviations: Ox oxaliplatin; +ox with oxaliplatin; Ox without oxaliplatin
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interaction term P= 0.78 and OS interaction term P= 1). Patients
with high-risk stage II tumours and CEA >2.35 ng/mL represent
25% of all stage II patients included in this post hoc analysis. The
addition of oxaliplatin had no survival advantage in patients with
low-risk stage II disease and CEA < 2.35 ng/mL (75% of the study
population; Fig. 3c–e; Table 3 and Supplementary Table S2).
These results were replicated for the OS endpoint (Fig. 4) and
using the modified MOSAIC definition for risk groups (Supple-
mentary Figs. S4 and S5). When assessed in the population aged
≤70 years, the predictive value of CEA level was also observed in
the high-risk group (Supplementary Figs. S6 and S7).
Similar results were observed with the optimal CEA cut-off value
of 2.77 ng/mL (Supplementary Table S3).
DISCUSSION
In this post hoc analysis of the MOSAIC study, post-operative
serum CEA level, with the cut-off of 2.35 ng/mL, was an
independent prognostic factor in CC patients with stage II disease.
Moreover, CEA appeared to be a predictive factor of the benefit
from the addition of oxaliplatin to LV5FU2 in adjuvant therapy for
high-risk stage II CC.
The prognostic value of post-operative CEA has been demon-
strated for stage I to IV CC.9 Our results are in line with the
literature, as we also showed that a lower cut-off of CEA is more
suitable level for death or recurrence risk stratification. The cut-off
values of 2.35 ng/mL (Margalit et al. study)7 and 2.77 ng/mL
(defined in our cohort study) suggest that the common 5 ng/mL
cut-off is clearly not optimal for risk stratification of patients with
CC. The magnitude of the prognostic value of the CEA level was
important in our study. Indeed, patients with high level of CEA
had a 50% increased risk of death or recurrence compared to
those who had CEA <2.35 ng/mL in multivariate analysis. We
analysed the post-operative CEA level given the results by Konishi
et al. who showed that the pre-operative CEA level is not a
relevant marker of recurrence in localised CC if CEA is normalised
after surgery.10
We showed in our study that only patients with high-risk stage II
CC and high post-operative CEA level benefited from the addition
of oxaliplatin in terms of DFS, with a 13% absolute increase in
3-year DFS rate. Another predictive factor of oxaliplatin benefit
that has been published, is a high-risk score with the Oncotype Dx
genomic signature.11 In fact, Yothers et al. showed, in a limited
cohort of patients, that only stage II CC with high risk Oncotype Dx
genomic signature seemed to benefit from the addition of
oxaliplatin to adjuvant therapy.
Circulating tumour DNA (ctDNA) has shown remarkable
prognostic value for OS and RFS in very small cohorts of patients
with early-stage CC.12–14 Lu et al. suggested that the combination
of post-operative serum CEA levels assessment and persistent
post-operative circulating tumour cells detection is prognostic
predictor of early relapse in stage II–III CC patients.15
All the above results suggest that a minimal residual disease
may be associated with ctDNA, circulating tumour cells, CEA, or
prognostic genomic signatures and that patients harbouring these
factors are those who can benefit most from treatment
intensification.
In our study, we used the risk groups definition published by
André et al in 2015 (T4, tumour perforation, or less than 10
examined lymph nodes). This definition was published in the
MOSAIC population, in order to lose as less information as
possible. As it is slightly different from the ESMO consensus
definition (12 lymph nodes examined instead of 10), we also
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Fig. 4 Benefit for OS with the addition of oxaliplatin to LV5FU2 in (a) all patients, (b) the MOSAIC low-risk patients, (c) the MOSAIC low-risk
patients after CEA stratification, (d) the MOSAIC high-risk patients, and (e) the MOSAIC high-risk patients after CEA stratification. Figure 4
abbreviations: Ox: oxaliplatin;+ ox: with oxaliplatin; Ox: without oxaliplatin
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definition). Moreover, in order to deal with potential confounding
factors related to comorbidities, we performed sensitivity analysis
in the ≤70 years’ population. Again, similar results were observed,
adding to their reliability.
In addition, in patients with high-risk stage II CC and post-
operative CEA >2.35 ng/mL most deaths occurred within 2 years
after surgery. This strongly suggest that post-operative imaging
including PET-scan should be performed in those patients in order
to further look at metastases before engaging adjuvant therapy,
especially in randomised clinical trials.
Our results are robust and obtained with the best material
available to study the interest to consider post-operative CEA
information among classical high and low-risk classification in order
to better identify patients who can benefit most from the addition
of oxaliplatin to LV5FU2. Ideally, our findings should be validated in
an external cohort data. Unfortunately, such data do not exist.
Indeed, no randomised trial that have studied the addition of
oxaliplatin to LV5FU2 in stage II CC patients provide precise post-
operative CEA data. Another limit of this study is the lack of
smoking habit data, a possible confusion factor. Therefore, clinician
should interpret these results with caution in smoking patients.
CONCLUSION
Our results show that post-operative CEA is a strong prognostic
factor for DFS and OS in stage II CC. In the MOSAIC trial, only high-
risk stage II CC with post-operative CEA >2.35 ng/mL (~25% of our
stage II population) were identified to benefit from the addition of
oxaliplatin to LV5FU2. CEA >2.35 ng/mL should be included in the
definition of high-risk stage II CC and should lead to post-operative
check-up before adjuvant therapy. Moreover, it should be included
in the future trials assessing adjuvant strategies in stage II CC.
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